DLA
HALO icon

Douglas Lane & Associates’s Halozyme HALO Stock Holding History

Douglas Lane & Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,500
Closed -$201K – 206
2020
Q2 		$201K Sell
7,500
-2,500
-25% -$56.4K ﹤0.01% 197
2020
Q1 		$180K Buy
+10,000
New +$190K ﹤0.01% 190

Other funds holding HALO

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Douglas Lane & Associates's HALO Position: Q3 2020 in Review

Douglas Lane & Associates sold out of Halozyme (HALO) in Q3 2020, closing a stake of 7,500 shares — an estimated $201K sold.

Douglas Lane & Associates first reported a position in HALO in Q1 2020 and held it in 2 quarters. The position peaked at $201K in Q2 2020. 268 funds tracked by Wall St. Rank hold HALO as of Q3 2020.

  • Douglas Lane & Associates reported no remaining Halozyme position as of Q3 2020 after selling out during the quarter.
  • Douglas Lane & Associates sold 7,500 Halozyme shares in Q3 2020, an estimated $201K.
  • Douglas Lane & Associates first reported a position in Halozyme in Q1 2020 and held it in 2 quarters.
  • Douglas Lane & Associates's Halozyme position peaked at $201K in Q2 2020.
  • 268 funds tracked by Wall St. Rank held Halozyme as of Q3 2020.

Based on Douglas Lane & Associates's 13F filing for Q3 2020, filed 19 Oct 2020.